---
title: "Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285902787.md"
description: "Kissei Pharmaceutical reported a fiscal 2026 net sales increase of 10.3% to ¥97.4 billion but faced an operating loss of ¥2.9 billion. Despite this, profit attributable to owners rose 15.2% to ¥13.8 billion. The company raised its annual dividend to ¥160 per share and forecasts a recovery to ¥4.4 billion in operating profit for the year ending March 2027, with projected net income of ¥14.5 billion. Analysts rate the stock as a Buy with a price target of ¥5400.00."
datetime: "2026-05-11T08:04:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285902787.md)
  - [en](https://longbridge.com/en/news/285902787.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285902787.md)
---

# Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Kissei Pharmaceutical Co ( (JP:4547) ).

Kissei Pharmaceutical reported fiscal 2026 net sales of ¥97.4 billion, up 10.3% year on year, but swung to an operating loss of ¥2.9 billion and an ordinary loss of ¥1.2 billion, while profit attributable to owners of parent rose 15.2% to ¥13.8 billion. The company strengthened its balance sheet, with total assets climbing to ¥275.1 billion and net assets to ¥231.5 billion, and it expanded shareholder returns by raising the annual dividend to ¥160 per share, including an 80th-anniversary commemorative payout, alongside moves to introduce a restricted stock incentive plan and execute share buybacks.

For the year to March 2027, Kissei forecasts slightly lower full-year sales of ¥95.7 billion but a recovery to ¥4.4 billion in operating profit and ¥6.0 billion in ordinary profit, with net income projected to increase to ¥14.5 billion. The guidance implies improved profitability despite modest top-line pressure and reflects the impact of treasury share disposal and repurchases on earnings per share, while a planned ¥170 annual dividend, again incorporating a commemorative element in the first half, underscores management’s commitment to capital efficiency and shareholder-friendly policies.

The most recent analyst rating on (JP:4547) stock is a Buy with a Yen5400.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

**More about Kissei Pharmaceutical Co**

Kissei Pharmaceutical Co., Ltd. is a Japan-based drugmaker listed on the Tokyo Stock Exchange that develops, manufactures and sells prescription pharmaceuticals. The company focuses on specialty areas such as urology, nephrology and other niche therapeutic fields, serving domestic and international markets through proprietary products and licensed drugs.

**YTD Price Performance:** -4.01%

**Average Trading Volume:** 88,707

**Technical Sentiment Signal:** Buy

**Current Market Cap:** Yen178.5B

For an in-depth examination of 4547 stock, go to TipRanks’ Overview page.

### Related Stocks

- [4547.JP](https://longbridge.com/en/quote/4547.JP.md)

## Related News & Research

- [Kissei Pharmaceutical's (TSE:4547) Solid Earnings May Rest On Weak Foundations](https://longbridge.com/en/news/286824222.md)
- [ADVISORY-Incorrectly tagged Kissei alert withdrawn](https://longbridge.com/en/news/286617469.md)
- [Revenue Beat: Furuya Metal Co., Ltd. Exceeded Revenue Forecasts By 55% And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/286657567.md)
- [JAC Recruitment (TSE:2124) EPS Jump In Q1 2026 Tests Cautious Market Narratives](https://longbridge.com/en/news/286545331.md)
- [K’S Holdings Corporation (8282) Gets a Buy from Mizuho Securities](https://longbridge.com/en/news/286239830.md)